Prelude Therapeutics Newsroom

Morgan Stanley Maintains Prelude Therapeutics(PRLD.US) With Sell Rating

Futu NewsDec 12 18:31 · Ratings

Prelude Therapeutics (PRLD) Gets a Sell From Morgan Stanley

TipRanksDec 12 18:28 · Ratings

Prelude Therapeutics Reports Promising Interim Data for PRT2527 in Relapsed/Refractory Lymphoid Malignancies, Plans Partnership for Future Development

BarchartDec 12 06:50

Express News | Prelude Therapeutics Inc: Plans to Seek a Partner for Future Development of PRT2527 in Hematologic Malignancies

BreakingsDec 11 20:31

Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies

GlobeNewswireDec 11 20:30

Express News | Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Patients With Relapsed/Refractory Lymphoid Malignancies

BreakingsDec 11 20:30

JMP Securities Maintains Prelude Therapeutics(PRLD.US) With Buy Rating, Cuts Target Price to $4

Futu NewsDec 11 13:33 · Ratings

After Plunging -31.47% in 4 Weeks, Here's Why the Trend Might Reverse for Prelude Therapeutics (PRLD)

Zacks Nov 27 21:40

Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit

GlobeNewswireNov 27 20:30

Prelude Therapeutics Reports Progress in Clinical Trials and Financial Health

TipRanksNov 26 12:02

Prelude Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow JonesNov 9 00:54 · Ratings

Prelude Therapeutics (PRLD) Receives a Sell From Barclays

TipRanksNov 8 17:51 · Ratings

Prelude Therapeutics | 8-K: Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

SECNov 7 11:32

Prelude Therapeutics Q3 EPS $(0.43) Beats $(0.47) Estimate

BenzingaNov 7 05:49

Prelude Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 7 05:32 · Announcements

Express News | Prelude Therapeutics Inc: Current Cash Runway Into 2026

BreakingsNov 7 05:27

Express News | Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

BreakingsNov 7 05:05

Press Release: Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Dow JonesNov 7 05:05

Prelude Therapeutics 3Q Loss/Shr 43c >PRLD

Dow JonesNov 7 05:05

Express News | Prelude Therapeutics Q3 Operating Expenses USD 37.376 Million

BreakingsNov 7 05:05